J. Zeng

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

Kim Papp, Mark Lebwohl, L. Puig et al. · British Journal of Dermatology · 2021 · 49 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +13

Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus

Peng Lü, Roy Fleischmann, C. Martin Curtis et al. · Lupus · 2017 · 32 citations

Medicine, Pharmacology, Pharmacotherapy +12

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a <i>post hoc</i> integrated analysis of patients with moderate‐to‐severe plaque psoriasis

Melinda Gooderham, Andreas Pinter, Laura K. Ferris et al. · Journal of the European Academy of Dermatology and Venereology · 2022 · 23 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +15

Defining trajectories of response in patients with psoriasis treated with biologic therapies

Nophar Geifman, Narges Azadbakht, J. Zeng et al. · British Journal of Dermatology · 2021 · 14 citations · Full text

Medicine, Clinical Sciences, Dermatology +17